Upstate Active Clinical Trials
Study Title:Bayer Protocol Number: 15983- A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
What is the purpose of the study?To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy
Upstate Institutional Review Board (IRB) Number:555426
Patient Age Group:Adults
Principal Investigator:Rahul Seth, DO
Who can I contact for more information?
Name: Wendy S Barry